NCT02508740View on ClinicalTrials.gov

Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment

PHASE1TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Renal Impairment
Interventions
DRUG

bevenopran

Single oral dose

Trial Locations (2)

55404

DaVita Clinical Research: Minneapolis Research Unit, Minneapolis

80228

DaVita Clinical Research: Denver Clinical Research Unit, Lakewood

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY